- Trials with a EudraCT protocol (765)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
765 result(s) found for: Colon Cancer AND Cancer.
Displaying page 22 of 39.
EudraCT Number: 2005-005738-11 | Sponsor Protocol Number: CRAD001C2445 | Start Date*: 2006-08-23 |
Sponsor Name:Unidad integral de investigación en oncologia | ||
Full Title: Phase II Study of Single Agent RAD001 in Patients with Colon Cancer and Activating Mutations in the PI3KCA gene. | ||
Medical condition: Colon Cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002794-11 | Sponsor Protocol Number: NL49960.018.14 | Start Date*: 2014-12-08 |
Sponsor Name:Academic Medical Center | ||
Full Title: Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicenter trial | ||
Medical condition: Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicenter trial | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003303-35 | Sponsor Protocol Number: IB2019-04 | Start Date*: 2021-04-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||||||||||||
Full Title: Combining epigenetic and immune therapy to beat cancer | ||||||||||||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004544-18 | Sponsor Protocol Number: CL2-95005-002 | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal ... | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004722-25 | Sponsor Protocol Number: 20060332 | Start Date*: 2008-07-15 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer | |||||||||||||
Medical condition: Colorectal cancer (CRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000613-32 | Sponsor Protocol Number: STEMNESS-CRC | Start Date*: 2020-07-24 | |||||||||||
Sponsor Name:1Globe Health Institute | |||||||||||||
Full Title: A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC (or BSC alone) in Adult Patients with Previo... | |||||||||||||
Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001402-18 | Sponsor Protocol Number: CIR-MSC-2014-01 | Start Date*: 2015-05-07 | |||||||||||
Sponsor Name:ALEJANDRA GARCIA BOTELLA | |||||||||||||
Full Title: CD133 + CELL INFUSION IN PATIENTS WITH COLORECTAL LIVER ORIGIN METASTASES GOING TO BE SUBMITTED TO A MAJOR LIVER RESECTION | |||||||||||||
Medical condition: patients with liver metastases from colorectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019815-40 | Sponsor Protocol Number: ML25359 | Start Date*: 2011-03-24 | |||||||||||
Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
Full Title: Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer | |||||||||||||
Medical condition: Patients with previously untreated metastatic colorectal carcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004418-32 | Sponsor Protocol Number: U31402-A-U202 | Start Date*: 2020-10-30 | |||||||||||
Sponsor Name:DAIICHI SANKYO, INC | |||||||||||||
Full Title: A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC) | |||||||||||||
Medical condition: Advanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, i... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001627-31 | Sponsor Protocol Number: CanStem303C | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc. | |||||||||||||
Full Title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) | |||||||||||||
Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) CZ (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007974-39 | Sponsor Protocol Number: AIO-KRK-0207 | Start Date*: 2009-08-04 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyr... | ||||||||||||||||||
Medical condition: Histologically confirmed and inoperable or irresectable metastatic colorectal cancer (stage IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004231-72 | Sponsor Protocol Number: IBICCR2018-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) | |||||||||||||
Full Title: Randomized study of the detection of RAS / BRAF mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer RAS / BRAF WT a... | |||||||||||||
Medical condition: Median of the progression-free survival of patients with mCRC who maintains the treatment in conventional 1st line, QT + anti-EFGR, versus patients who withdraw anti-EGFR therapy after detection of... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003835-12 | Sponsor Protocol Number: AC17067 | Start Date*: 2018-03-01 | |||||||||||||||||||||
Sponsor Name:The University Of Edinburgh [...] | |||||||||||||||||||||||
Full Title: A placebo controlled randomised trial of intravenous lidocaine in accelerating gastrointestinal recovery after colorectal surgery | |||||||||||||||||||||||
Medical condition: Patients scheduled for elective colorectal resection for colorectal cancer or diverticular disease. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023562-51 | Sponsor Protocol Number: BT-CL-PGG-CRC1031 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Biothera | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004505-29 | Sponsor Protocol Number: 2676 | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:Royal Marsden NHS Trust | |||||||||||||
Full Title: Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer | |||||||||||||
Medical condition: Metastatic colorectal adenocarcinoma with metastases involving the liver only | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003804-15 | Sponsor Protocol Number: SGMCBM | Start Date*: 2023-12-19 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: A FEASIBILITY STUDY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF COLORECTAL BRAIN METASTASES | ||||||||||||||||||
Medical condition: Colorectal brain metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date*: 2023-04-24 | ||||||||||||||||
Sponsor Name:Amsterdam University Medical Centers | ||||||||||||||||||
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003244-23 | Sponsor Protocol Number: SICOG13/02 | Start Date*: 2014-03-19 | |||||||||||
Sponsor Name:S.I.C.O.G. ONLUS | |||||||||||||
Full Title: B-FOLFIRI followed by B-FOLFOX/B-XELOX or the reverse sequence versus standard B-FOLFIRI for the first-line treatment of metastatic colorectal cancer: a randomized SICOG study. SEveSTA study (Seq... | |||||||||||||
Medical condition: Unresectable and metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023580-18 | Sponsor Protocol Number: 62202-529 | Start Date*: 2011-05-04 | |||||||||||
Sponsor Name:Merck, S.L | |||||||||||||
Full Title: Ensayo clínico fase II, de cetuximab en cáncer colorrectal metastático refractario con K-RAS mutado y genotipos FcyRII/IIIa favorables Phase II clinical study of cetuximab in refractory colorectal ... | |||||||||||||
Medical condition: Sujetos con CCRm, estadio IV, refractario al tratamiento estándar, que presentan el gen K-RAS mutado y genotipos FcγRII/IIIa favorables, con genotipos FcγRIIa-131H/H y/o FcγRIIIa 158V/V | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000846-37 | Sponsor Protocol Number: TTD-12-01 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD) | |||||||||||||
Full Title: Phase III, randomized clinical trial to evaluate FOLFOX + bebacizumab versus FOLFOXIRI + bebacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and... | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
